Overton FDA Nomination Stalls; Brenner Considered

With Democrats sweeping Congress, the administration's plan to confirm Heidi Overton as FDA commissioner has become infeasible.

Updated on Nov. 10, 2026 in Healthcare

Flat-color editorial illustration of a single empty leather chair on a long wooden dais in a plain hearing chamber, set in deep red and cream. — The Trump administration has stalled the confirmation of Heidi Overton as FDA commissioner after Democrats won control of Congress, and is weighing Sara Brenner as acting head. AI Illustration. Upload story photo >

The Trump administration's attempt to confirm Heidi Overton as FDA commissioner has become infeasible following Democratic gains in the midterm elections. Sara Brenner, a former acting FDA commissioner, is being considered as an acting replacement for Kyle Diamantas.

Why it matters

The Democratic sweep of Congress upends the administration's plans to reshape leadership at HHS and the FDA. The shift leaves the agency's top post in flux as the administration prepares for a contest with a Democratic-controlled Congress.

No hard corporate or operational figures are included in the source extraction. The story turns on a personnel shift at the FDA, with the key measurable change being the loss of a planned confirmation pathway for Heidi Overton.

The players

Robert F. Kennedy Jr.

Secretary of Health and Human Services, whose allies have been elevated within the administration as leadership changes unfold.

Susie Wiles

Former White House chief of staff who was pushed out and had served as an intermediary between business interests, including pharmaceutical companies, and Trump loyalists.

Mehmet Oz

Administrator of the Centers for Medicare & Medicaid Services, who was considered as a potential replacement for Kennedy at HHS.

Sara Brenner

Former acting FDA commissioner now being considered to replace Kyle Diamantas in the acting role.

The details

Susie Wiles, who served as an intermediary between business interests, including pharmaceutical companies, and Trump loyalists, was pushed out as White House chief of staff. The administration has elevated officials aligned with HHS Secretary Robert F. Kennedy Jr., and a plan to replace Kennedy with CMS Administrator Mehmet Oz has also become infeasible.

Midterm elections (November 2026): Democrats won and swept Congress, which will be Democratic-controlled.
Article published November 10, 2026, reporting on the FDA leadership shakeup.

Market Landscape

The Democratic takeover of Congress following the 2026 midterm elections makes Senate confirmation of Trump-aligned health nominees far harder to secure. The shift places the FDA and HHS leadership fight at the center of the administration's broader confrontation with the new Congress.

Leadership uncertainty at the FDA could slow decisions on drug approvals and regulatory guidance that affect the medicines Americans use. With no confirmed commissioner expected for the rest of the administration, the agency's direction may depend on acting leadership.

The takeaway

Leadership changes at federal health agencies can shift regulatory priorities quickly, so readers tracking drug approvals should watch who is named acting FDA commissioner. Confirmation politics will likely grow more contentious with a Democratic-controlled Congress.